logo

MDGL

Madrigal·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

MDGL fundamentals

Madrigal (MDGL) released its earnings on Nov 4, 2025: revenue was 287.27M (YoY +361.85%), beat estimates; EPS was -5.08 (YoY -3.25%), missed estimates.
Revenue / YoY
287.27M
+361.85%
EPS / YoY
-5.08
-3.25%
Report date
Nov 4, 2025
MDGL Earnings Call Summary for Q3,2025
  • Revenue Surge: Q3 2025 sales $287M (+35% QoQ), annualizing >$1B with 29,500+ patients on therapy.
  • Payer Triumph: 2026 contracts secure first-line access, gross-to-net to rise to high 30% in 2026.
  • Pipeline Power: Phase 3 F4C trial on track for 2027 readout, GLP-1 combo MGL-2086 Phase 1 starts H1 2026.
  • Global Growth: Germany launch underway, targeting 315,000 diagnosed F2-F3 patients with 90%+ untreated market share.
EPS
Revenue

Revenue & Expenses

MDGL has released its 2025 Q3 earnings report, with revenue of 287.27M, reflecting a YoY change of 362.03%, and net profit of -114.19M, showing a YoY change of -6.76%. The Sankey diagram below clearly presents MDGL's revenue sources and cost distribution.

Key Indicators

Madrigal (MDGL) key financial stats and ratios, covering profitability, financial health, and leverage.
Madrigal (MDGL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Madrigal (MDGL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Madrigal (MDGL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Madrigal (MDGL) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Madrigal (MDGL) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield